Where the benefit claims come from

Skin texture, fine lines and wrinkles

In 20 women using a GHK-Cu formulation and a control on opposite sides of the face, mean wrinkle volume decreased 24.1% versus 15.0% from baseline over eight weeks. Mean depth decreased 20.3% versus 15.3%. The control lacked both the peptide and its lipid carrier, so the findings apply to the finished formulation. Badenhorst and colleagues’ wrinkle study.

A separate randomized trial tested topical GHK-Cu regimens after CO2 laser resurfacing; 13 people completed it. At 12 weeks, GHK-Cu users were more satisfied with their skin, but blinded assessments found no significant additional improvement in wrinkles, redness or overall skin quality. Miller and colleagues’ skin trial.

Those topical results do not predict how much an injected GLOW blend would change wrinkles.

Collagen production, firmness and elasticity

GHK-Cu increased collagen production in cultured fibroblasts without increasing their number. These cells build the connective material that supports skin, which explains the interest in firmness. Maquart and colleagues’ collagen study.

Another cell experiment measured roughly 30% more elastin after 96 hours of GHK-Cu exposure, using three replicates. That is a protein measurement, not a percentage improvement in skin elasticity. Badenhorst and colleagues’ cell experiments.

To establish firmer or more elastic skin as a GLOW benefit, those changes would need to be measured in people receiving the actual blend.

Wound closure and scar appearance

Within a randomized diabetic-foot-ulcer trial, 28 patients received topical GHK-Cu gel immediately after removal of damaged tissue and 32 received its inactive base. In this sole-of-the-foot subgroup, median ulcer-area reduction was 98.5% versus 60.8%. Both groups received wound care and pressure-relieving footwear; treatment lasted up to eight weeks, with six further weeks of observation. The result used each patient’s last assessment. Mulder and colleagues’ ulcer trial.

The percentages describe how much smaller the wounds became, rather than the proportion of people completely healed. This is evidence about that gel alongside wound care for a specific kind of ulcer.

Scar appearance has a separate experimental finding. In skin fibroblasts associated with keloids, a type of raised scar, copper tripeptide reduced release of the scarring signal TGF-beta1 at 24 hours. The study used cells grown from surgical skin samples. It did not measure whether an existing scar became flatter, paler or less itchy. McCormack and colleagues’ scar-cell study.

Joint pain and comfort

In a small 2021 retrospective report, 11 of 12 people receiving BPC-157 alone and three of four receiving it with thymosin beta-4 described less knee pain. The preparations were injected into the knee joint. Sixteen of 17 patients were reached by telephone; most had received their injection six to 12 months earlier. There was no untreated comparison group. Lee and Padgett’s knee-pain report.

That is an early observation about symptom relief. The report did not use standardized function assessments or demonstrate tissue repair on follow-up imaging. It therefore cannot show that cartilage regrew, a tear healed or surgery became unnecessary.

Tendon, muscle, ligament, bone and nerve repair

Pain relief and physical repair need different measurements. Researchers have tested BPC-157 in several surgically created animal injuries, looking at strength, movement, tissue attachment and electrical nerve responses.

Group sizes were not reported in the original abstracts for the tendon, ligament, bone and nerve studies. All five papers share some investigators; they cover different injuries without providing five independent replications.

These experiments measured repair after severe, deliberately created injuries. They did not test ordinary post-workout soreness, muscle growth or return to training in people. A 14-day rat study therefore cannot establish a two-week human recovery time.

Hair growth

Topical full-length thymosin beta-4 roughly doubled the number of follicles in the active growth phase after seven days in a rat experiment, compared with the control preparation. The comparison used treated and control areas on the same rats; groups contained three to five animals. Active-follicle counts stayed elevated during 30 days of treatment, then returned to control levels within 14 days of stopping. Philp and colleagues’ hair-growth experiment.

This was a shift toward the hair-growth phase in animals, not evidence that GLOW creates twice as many follicles or reverses human hair loss. Whether any human improvement would last after stopping remains unanswered.

Gut inflammation and bloating

In a 32-mouse colitis experiment, with eight animals per group, 14 days of orally delivered GHK-Cu reduced a disease score based on weight loss, stool consistency and blood in the stool. Colon-injury measures improved, and proteins involved in the intestinal barrier were better preserved. Mao and colleagues’ colitis study.

This concerns chemically induced inflammation of the colon. It gives the intestinal-inflammation claim an experimental basis, but does not answer whether GLOW relieves everyday bloating or reduces inflammation throughout the human body.

Does combining the peptides increase the benefit?

To show that GLOW offers an added benefit, researchers would need to compare the blend with its individual ingredients under the same conditions.

A 2026 rat Achilles-repair experiment compared BPC-157, a preparation the authors describe as synthetic thymosin beta-4 or TB-500, and their combination. At the day-30 endpoint, the authors reported no consistent advantage from combining them. Only four tendons per group underwent strength testing. Biçer and colleagues’ combination study.

The experiment omitted GHK-Cu and was too small to settle whether combinations could help under other conditions. It supplies no evidence that adding a third ingredient improves the result.

Molecule names matter here, too. Wound experiments have tested full-length thymosin beta-4 and a separate, seven-amino-acid fragment. A finding for one preparation should not automatically be assigned to everything described as TB-500. Philp and colleagues’ wound study. The GLOW peptide stack guide explains the ingredient and label distinctions in more detail.

Can these studies predict your results?

They cannot provide a reliable GLOW success rate or a timetable for visible results. The outcome would need to be measured using the complete blend: wrinkle changes for a skin claim, hair counts for regrowth, or strength and function for injury recovery. The GLOW peptide research guide examines the human studies and their methods in more detail.

A personal photograph can document appearance, but it cannot isolate the effect of GLOW from skin care, other treatments or changing photo conditions. The GLOW before-and-after guide shows how to assess those differences.

Potential benefits also need to be weighed against GLOW peptide side effects. FDA identifies limited human safety information for BPC-157 and injectable GHK-Cu, including potential immune-response concerns. FDA’s substance-specific safety information.

For claims built around a particular amount or schedule, the GLOW peptide dosage guide explains which numbers describe the product and which would require clinical evidence.

Evidence checked September 14, 2026. This article uses the cited original studies and their abstracts; it is not a systematic review.